Clinical Trials · NCT00191802

Compliance and Acceptance of Teriparatide Injection in Severely Osteoporotic Patients

Name: Compliance and Acceptance of Teriparatide Injection in Severely Osteoporotic Patients
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Teriparatide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Eli Lilly and Company
Enrollment: 120
Start date: Sep 2003
Locations: 13 sites, Canada
Primary endpoint: The primary objective is to determine the acceptance of, and compliance with, 6 months of teriparatide subcutaneous injections in patients with severe osteoporosis who have failed on OR are intolerant to currently available osteoporosis therapies.

View Teriparatide compound reference